Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
AstraZeneca
Mallinckrodt
Baxter
McKesson

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 8,877,710

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,877,710
Title:Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
Abstract: The present invention relates to compounds for treatment that protects the endothelium, prevent pathologic thrombus formation in the microcirculation and preserve platelet number and function and thus may be related to minimizing or preventing development of organ failure, including multiple organ failure (MOF), and, hence, death in critically ill patients by administration of agent(s) limiting the platelets ability to aggregate and form clots and/or by agents modulating/preserving endothelial integrity and/or by agent(s) increasing the rate of thrombus lysis, and Another aspect of the invention related to by a cell-based whole blood viscoelastical haemostatic assay identifying critically ill patients at increased risk of development of organ failure, including multiple organ failure (MOF) and death.
Inventor(s): Johansson; Par (Dosjebro, SE), Ostrowski; Sisse Rye (Hellerup, DK)
Assignee: Righospitalet (Kobenhavn O, DK)
Application Number:13/142,935
Patent Claims:1. A method for the preservation of platelet number and/or function in a critically ill patient having thrombocytopenia, comprising administering to a patient in need thereof a combination of (1) one or more compounds selected from the group consisting of platelet inhibitors, wherein the platelet inhibitor is capable of inhibiting the GPIIb/IIIa receptor, and (2) one or more compounds capable of modulating/preserving the endothelial integrity wherein the compound capable of modulating/preserving the endothelial integrity is selected from the group consisting of PGI2, PGX, and prostacyclin or variants thereof, thereby treating or reducing risk of organ failure in said patient in need thereof.

2. The method of claim 1, wherein the platelet inhibitor is capable of inhibiting the GPIIb/IIIa receptor and the compound capable of modulating/preserving the endothelial integrity is PGI2 or a variant thereof.

3. The method of claim 1, wherein the platelet inhibitor is selected from the group consisting of abciximab, eptifibatide, tirofiban, orbofiban, xemilofiban, lamifiban, XJ757, DUP728 and XR299.

4. The method of claim 1, wherein the platelet inhibitor has a half-life of less than 3 hours.

5. The method of claim 1, wherein the prostacyclin variant is selected from the group consisting of beraprost sodium, epoprostenol sodium, iloprost, iloprost in combination with bosentan, iloprost in combination with sildenafil citrate, treprostinil, pegylated treprostinil, treprostinil diethanolamine and treprostinil sodium, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfony- l)acetamide, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid, 8-[1,4,5-triphenyl-1H-imidazol-2-yl-oxy]octanoic acid, isocarbacyclin, cicaprost, [4-[2-(1,1-Diphenylethylsulfanyl)-ethyl]-3,4-dihydro-2H-benzo[1,4]oxazin-- 8-yloxy]-acetic acid N-Methyl-d-glucamine, 7,8-dihydro-5-(2-(1-phenyl-1-pyrid-3-yl-methiminoxy)-ethyl)-a-naphthyloxy- acetic acid, (5-(2-diphenylmethyl aminocarboxy)-ethyl)-a-naphthyloxyaceticacid, 2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid, [3-[4-(4,5-diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid, bosentan, 17[alpha], 20-dimethyl-[DELTA]6,6a-6a-carba PGI1, 15-deoxy-16[alpha]-hydroxy-16[beta], 20-dimethyl-[DELTA]6,6a-6a-carba PGI1 and pentoxifylline (1-{5-oxohexyl}-3,7-dimethylxanthine).

6. The method of claim 1, wherein the compound capable of modulating/preserving the endothelial integrity has a half-life of less than 4 hours.

7. The method of claim 1, wherein organ failure is multiple organ failure (MOF) or thrombocytopenia associated multi organ failure (TAMOF).

8. The method of claim 1, wherein organ failure is due to systemic inflammation or due to severe infections or due to sepsis or due to systemic inflammatory response syndrome (SIRS) and/or compensatory anti-inflammatory response syndrome (CARS) or due to coagulopathy or due to trauma and/or burns or due to malignant diseases or due to ischemia or due to cardiovascular thromboembolic diseases or due to intoxication.

9. The method according to claim 1, wherein the organ or organs, which are subject to failure are selected from the group consisting of cardiovascular, respiratory, renal, haematological, neurological, gastrointestinal and hepatic organs and musculoskeletal organs.

10. A method of treating or reducing risk of organ failure in an acutely ill patient having thrombocytopenia, comprising administering to a patient in need thereof a combination of (1) one or more compounds selected from the group consisting of platelet inhibitors, wherein the platelet inhibitor is capable of inhibiting the GPIIb/IIIa receptor, and (2) one or more compounds capable of modulating/preserving the endothelial integrity wherein the compound capable of modulating/preserving the endothelial integrity is selected from the group consisting of PGI2, PGX, and prostacyclin or variants thereof, thereby treating or reducing risk of organ failure in said patient in need thereof.

11. The method of claim 10, wherein the platelet inhibitor is capable of inhibiting the GPIIb/IIIa receptor and the compound capable of modulating/preserving the endothelial integrity is PGI2 or a variant thereof.

12. The method of claim 10, wherein the platelet inhibitor is selected from the group consisting of abciximab, eptifibatide, tirofiban, orbofiban, xemilofiban, lamifiban, XJ757, DUP728 and XR299.

13. The method of claim 10, wherein the platelet inhibitor has a half-life of less than 3 hours.

14. The method of claim 10, wherein the pro stacyclin variant is selected from the group consisting of beraprost sodium, epoprostenol sodium, iloprost, iloprost in combination with bosentan, iloprost in combination with sildenafil citrate, treprostinil, pegylated treprostinil, treprostinil diethanolamine and treprostinil sodium, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfony- l)acetamide, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid, 8-[1,4,5-triphenyl-1H-imidazol-2-yl-oxy]octanoic acid, isocarbacyclin, cicaprost, [4-[2-(1,1-Diphenylethylsulfanyl)-ethyl]-3,4-dihydro-2H-benzo[1,4]oxazin-- 8-yloxy]-acetic acid N-Methyl-d-glucamine, 7,8-dihydro-5-(2-(1-phenyl-1-pyrid-3-yl-methiminoxy)-ethyl)-a-naphthyloxy- acetic acid, (5-(2-diphenylmethyl aminocarboxy)-ethyl)-a-naphthyloxyaceticacid, 2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid, [3-[4-(4,5-diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid, bosentan, 17[alpha], 20-dimethyl-[DELTA]6,6a-6a-carba PGI1, 15-deoxy-16[alpha]-hydroxy-16[beta], 20-dimethyl-[DELTA]6,6a-6a-carba PGI1 and pentoxifylline (1-{5-oxohexyl}-3,7-dimethylxanthine).

15. The method of claim 10, wherein the compound capable of modulating/preserving the endothelial integrity has a half-life of less than 4 hours.

16. The method of claim 10, wherein organ failure is multiple organ failure (MOF) or thrombocytopenia associated multi organ failure (TAMOF).

17. The method of claim 10, wherein organ failure is due to systemic inflammation or due to severe infections or due to sepsis or due to systemic inflammatory response syndrome (SIRS) and/or compensatory anti-inflammatory response syndrome (CARS) or due to coagulopathy or due to trauma and/or burns or due to malignant diseases or due to ischemia or due to cardiovascular thromboembolic diseases or due to intoxication.

18. The method according to claim 10 wherein the organ or organs, which are subject to failure are selected from the group consisting of cardiovascular, respiratory, renal, haematological, neurological, gastrointestinal and hepatic organs and musculoskeletal organs.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Boehringer Ingelheim
Colorcon
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.